Praxis Precision Medicines, Inc. (PRAX) — Institutional Holders, Q2 2026 (page 4)

311 institutional investment managers reported a PRAX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $11.3B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 301 to 311. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

PRAX 13F holders ranked 301–311 of 311

Institutional investors reporting a position in Praxis Precision Medicines, Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Bogart Wealth#301 · 2 sh$670.00+100.0%
Versant Capital Management#302 · 2 sh$670.000.0%
SJS Investment Consulting#303 · 2 sh$670.00-50.0%
Fortitude Family Office#304 · 2 sh$670.00-71.4%
Silver Grove Financial Group#305 · 2 sh$670.00New
ASSETMARK#306 · 1 sh$335.00New
Ameritas Advisory Services#307 · 1 sh$335.00New
Kilter Group#308 · 1 sh$335.00New
NOMURA ASSET MANAGEMENT LTD#309 · 0 sh$0.00New
Persistent Asset Partners Ltd#310 · 0 sh$0.00-100.0%
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#311 · 26,603 sh—-3.2%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.